- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| RAPPORT THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 07.05. | Raymond James reiterates Strong Buy on Rapport Therapeutics stock | 3 | Investing.com | ||
| 07.05. | Rapport Therapeutics GAAP EPS of -$0.42, revenue of $0.02M | 4 | Seeking Alpha | ||
| 07.05. | Rapport Therapeutics, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 07.05. | Rapport Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 21.04. | Rapport Therapeutics reports extended efficacy data for RAP-219 | 3 | Investing.com | ||
| 21.04. | Rapport Therapeutics, Inc.: Rapport Therapeutics Presents RAP-219 Focal Onset Seizure Phase 2a Follow-up Period Results Demonstrating Sustained Seizure Reduction at the 2026 American Academy of Neurology Annual Meeting | 2 | GlobeNewswire (USA) | ||
| 21.04. | Rapport Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 01.04. | Rapport Therapeutics, Inc.: Rapport Therapeutics to Present New Phase 2 Treatment Follow-Up Data for RAP-219 in Focal Onset Seizures at the 2026 American Academy of Neurology Annual Meeting | 3 | GlobeNewswire (USA) | ||
| 16.03. | Truist reiterates Rapport Therapeutics stock rating on phase 3 plans | 4 | Investing.com | ||
| 16.03. | Rapport Therapeutics: Truist bestätigt Kaufempfehlung nach beschleunigten Phase-3-Plänen | 11 | Investing.com Deutsch | ||
| 11.03. | Stifel reiterates Rapport Therapeutics stock rating after results | 5 | Investing.com | ||
| 11.03. | Jones Trading reiterates Rapport Therapeutics stock rating on epilepsy progress | 4 | Investing.com | ||
| 11.03. | BTIG raises Rapport Therapeutics stock price target on trial progress | 2 | Investing.com | ||
| 10.03. | Rapport Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 10.03. | Rapport Therapeutics GAAP EPS of -$0.72 misses by $0.03 | 1 | Seeking Alpha | ||
| 10.03. | Rapport Therapeutics, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 10.03. | Rapport Therapeutics, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 10.03. | Rapport Therapeutics, Inc.: Rapport Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update | 469 | GlobeNewswire (Europe) | RAP-219's lead program demonstrated robust and consistent activity in patients with focal onset seizures (FOS) in Phase 2a trial; initiation of Phase 3 program expected in the second quarter of 2026RAP-... ► Artikel lesen | |
| 10.03. | Citizens reiterates Rapport Therapeutics stock rating on seizure drug potential | 1 | Investing.com | ||
| 10.03. | Citizens bekräftigt Rating für Rapport Therapeutics wegen Potenzial bei Epilepsie-Wirkstoff | 2 | Investing.com Deutsch |
1 2 Weiter >>
34 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VIKING THERAPEUTICS | 26,950 | +0,94 % | Viking Therapeutics, Inc.: Viking Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update | Conference call scheduled for 4:30 p.m. ET today
-- Phase 3 VANQUISH Trials for Subcutaneous VK2735 in Obesity Advance; VANQUISH-1 and VANQUISH-2 Trials Fully Enrolled... ► Artikel lesen | |
| BIOCRYST PHARMACEUTICALS | 8,242 | +9,89 % | BioCryst Ireland, a Neopharmed Gentili company: Hereditary angioedema, a European initiative to shine a spotlight on a still under-recognized condition | Ahead of World HAE Day, BioCryst Ireland, a Neopharmed Gentili company, organised an international event in Milan bringing together leading experts from across Europe to raise awareness of... ► Artikel lesen | |
| IMMUNITYBIO | 7,080 | +2,31 % | ImmunityBio Stock Drops After Earnings Miss Despite Anktiva Momentum | ||
| MICROBOT MEDICAL | 1,905 | +2,42 % | Microbot Medical Inc.: Microbot Medical Announces the Addition of Senior Commercial Executive with Proven Track Record to Accelerate Commercial Readiness in Europe, the Middle East, and Asia (EMEA) | Commencement of activities in international markets is supported by the successful completion of the Limited Market Release, followed by the Recent Full Market Release in the U.S. Strong physician... ► Artikel lesen | |
| ATAIBECKLEY | 3,660 | +3,98 % | Trump zündet den Turbo: Warum AtaiBeckley und Emyria jetzt im Fokus der Anleger stehen | ||
| CARDIFF ONCOLOGY | 1,435 | +2,43 % | Cardiff Oncology, Inc.: Cardiff Oncology Announces Key Leadership Appointments to Strengthen Executive Team for Next Phase of Growth | Board member and Interim CEO Mani Mohindru, PhD, named President and Chief Executive OfficerAppoints industry veterans Josh Muntner as Chief Financial Officer and Ajay Aggarwal, MD, MBA, as Chief... ► Artikel lesen | |
| CYTOKINETICS | 66,10 | +3,77 % | Cytokinetics presents new data on heart drug aficamten | ||
| FATE THERAPEUTICS | 1,644 | -14,06 % | Fate Therapeutics, Inc.: Fate Therapeutics Reports First Quarter 2026 Financial Results and Business Updates | RECLAIM - LN, a Phase 2 potentially registrational clinical trial of FT819 in patients with refractory moderate-to-severe systemic lupus erythematosus (SLE) with lupus nephritis, on schedule to initiate... ► Artikel lesen | |
| VOYAGER THERAPEUTICS | 3,766 | +6,69 % | Voyager Therapeutics, Inc.: Voyager ASGCT Late Breaker: Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 3-Month GLP Toxicology Data; Clinical Trial in Alzheimer's Disease Expected H2 2026 | - VY1706 IND application process on track for Q2 2026; clinical entry expected H2 2026 - - Data from eight ASGCT presentations highlight Voyager's continued innovation in gene therapy - LEXINGTON... ► Artikel lesen | |
| ARCTURUS THERAPEUTICS | 8,270 | +0,24 % | Arcturus outlines 12-week ARCT-032 Phase II enrollment and extends cash runway beyond Q2 2028 | ||
| PALISADE BIO | 1,880 | -2,08 % | Palisade Bio, Inc.: Palisade Bio Reports First Quarter 2026 Financial Results and Highlights Continued Clinical Progress of PALI-2108 | Advancing potentially best-in-class once-daily oral, locally-activated PDE4 inhibitor prodrug for treatment of IBD Phase 2 Ulcerative Colitis (UC) trial expected to commence 3Q 2026 Strong balance... ► Artikel lesen | |
| CAPRICOR | 25,400 | -5,29 % | Capricor stock price target held at $63 by B.Riley on FDA progress | ||
| REGENXBIO | 8,476 | -2,86 % | Bronstein, Gewirtz & Grossman, LLC: Bronstein, Gewirtz & Grossman LLC Urges REGENXBIO Inc. Investors to Act: Class Action Filed Alleging Investor Harm | New York, New York--(Newsfile Corp. - April 14, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed... ► Artikel lesen | |
| BIOAGE LABS | 16,060 | +3,55 % | BioAge Labs, Inc.: BioAge Labs Reports First Quarter 2026 Financial Results and Provides Business Updates | Positive topline Phase 1 data for BGE-102, demonstrating potential best-in-class reductions among oral NLRP3 inhibitors in inflammatory biomarkers of cardiovascular risk Phase 2 dose-ranging proof-of-concept... ► Artikel lesen | |
| ZEVRA THERAPEUTICS | 9,400 | +2,17 % | Zevra outlines Celiprolol interim analysis trigger at 28 events while expanding MIPLYFFA access |
RAPPORT THERAPEUTICS INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von +0,860 (+2,31 %) liegt der Kurs bei 38,100 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu RAPPORT THERAPEUTICS INC finden Sie auf Wallstreet Online.